Ventas Stock Rallies 24.5% in Six Months: Will the Trend Last?
VTR shares rise 24.5% in six months, far outperforming the industry, as strong SHOP growth and balance sheet gains lift sentiment.
Key Reasons to Add Ventas Stock to Your Portfolio Right Now
VTR gains momentum as its healthcare real estate portfolio, research investments and solid balance sheet point to further growth potential.
Why Is Ventas (VTR) Up 7.7% Since Last Earnings Report?
Ventas (VTR) reported earnings 30 days ago. What's next for the stock?
Are You Looking for a Top Momentum Pick? Why Ventas (VTR) is a Great Choice
Does Ventas (VTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ventas Stock Rallies 16.2% in Three Months: Will It Continue to Gain?
VTR's expanding SHOP footprint, rising cash NOI and active capital recycling underscore its growth momentum.
Ventas, Inc. (VTR) Q3 2025 Earnings Call Transcript
Ventas, Inc. ( VTR ) Q3 2025 Earnings Call October 30, 2025 10:00 AM EDT Company Participants Bill Grant - Senior Vice President of Investor Relations Debra Cafaro - Chairman & CEO J. Hutchens - Executive VP of Senior Housing & Chief Investment Officer Robert Probst - Executive VP & CFO Peter Bulgarelli - Executive Vice President of Outpatient Medical & Research Conference Call Participants Jonathan Hughes - Raymond James & Associates, Inc., Research Division Michael Carroll - RBC Capital Markets, Research Division Farrell Granath - BofA Securities, Research Division Vikram Malhotra - Mizuho Securities USA LLC, Research Division Michael Goldsmith - UBS Investment Bank, Research Division Nicholas Joseph - Citigroup Inc., Research Division Richard Anderson - Cantor Fitzgerald & Co., Research Division Samuel Ademola Ohiomah - Deutsche Bank AG, Research Division Juan Sanabria - BMO Capital Markets Equity Research William John Kilichowski - Wells Fargo Securities, LLC, Research Division Ronald Kamdem - Morgan Stanley, Research Division Michael Stroyeck - Green Street Advisors, LLC, Research Division Michael Mueller - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by.
Ventas Q3 FFO and Revenues Beat Estimates, Same-Store Cash NOI Rises
VTR posts strong Q3 results with higher FFO and revenues, fueled by gains in senior housing and outpatient medical portfolios.
Ventas (VTR) Q3 FFO and Revenues Top Estimates
Ventas (VTR) came out with quarterly funds from operations (FFO) of $0.88 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to FFO of $0.8 per share a year ago.
What's in the Offing for Ventas Stock This Earnings Season?
While VTR's Q3 earnings are likely to have benefited from SHOP operating trends and a well-diversified tenant base, high interest expenses may have hurt it.
4 Reasons To Buy Ventas And Take Advantage Of Future Returns
Ventas is a leading healthcare REIT, poised for growth due to rising senior housing demand and a strategic focus on the SHOP segment. Only WELL is the major competitor in SHOP, while the others are betting on other types of segments and triple-net leasing. Despite trading at a premium (20x P/FFO), VTR offers a compelling total return thesis, targeting a 25% upside to $86.50 and dividend growth potential.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
Why Ventas (VTR) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?
